Correction: Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Advancing Beyond Inhibition: Utilizing the DRD2–VEGF-A Feedback Mechanism for Targeted Anti-Angiogenesis Treatment in Oncology

  • By

  • Manas Ranjan Sahu

  • Venu Akkanapally

  • Partha Sarathi Dasgupta

  • Sujit Basu

  • September 2, 2026

Share

Clinical Scorecard: Correction: Advancing Beyond Inhibition: Utilizing the DRD2–VEGF-A Feedback Mechanism for Targeted Anti-Angiogenesis Treatment in Oncology

At a Glance

CategoryDetail
ConditionOncology
Key MechanismsDRD2-VEGF-A feedback loop
Target PopulationCancer patients
Care SettingPrecision anti-angiogenesis therapy

Key Highlights

  • Correction of funding statement
  • Clarification of grant information
  • Support from Ohio State University Comprehensive Cancer Center

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Cancer patients receiving anti-angiogenesis therapy

          Utilization of DRD2-VEGF-A feedback mechanism

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

            • by Manas Ranjan Sahu, Venu Akkanapally, Partha Sarathi Dasgupta, Sujit Basu

            • September 2, 2026

            Related Content

            This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

            A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

            • August 31, 2026

            • 5 min
            Genetic Testing in Retinoblastoma: New Applications

            Liquid biopsy and molecular profiling are expanding the diagnostic and prognostic role of genetic testing in retinoblastoma.

            Statins use and prognosis in lung cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis